An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer-Reference-Cited by-同舟云学术

An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

Published:2003-08 Issue:2 Volume:62 Page:319-323
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Sartor Oliver,Dineen Martin K,Perez-Marreno Ramon,Chu Franklin M,Carron Graham J,Tyler Robert C

Publisher

Elsevier BV

Subject

Urology

Reference20 articles.

1. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer;Sharifi;Clin Ther,1996

2. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer;Tunn;Urol Int,1998

3. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer;Sharifi;Urology,1998

4. Update of the NCCN guidelines for treatment of prostate cancer;Millikan;Oncology (Huntingt),1997

5. NCCN practice guidelines for prostate cancer;Bahnson;Oncology (Huntingt),2000

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic;Drug Delivery and Translational Research;2022-08-17

2. Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections;Journal of Controlled Release;2022-08

3. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD®) in Asian men with prostate cancer;Translational Andrology and Urology;2022-02

4. Resetting the Bar of Castration Resistance – Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer;Clinical Genitourinary Cancer;2021-06

5. The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy;Meditsinskiy sovet = Medical Council;2020-12-21